Amnis announced that it received approval to perform a First-in-Human clinical trial with its neuro thrombectomy device, the Golden Retriever. The approval was received from the Karolinska Institute (Stockholm, Sweden). Prof. Tommy Andersson, a neuro-surgeon and vascular interventionalist will be the trial's principal investigator. The trial will include 60 patients suffering from Acute Ischemic Stroke, with a large intracerebral vessel occlusion. The company will start recruiting patients shortly and expects the trial to conclude during first quarter of, 2018. The physicians will use the Golden Retriever to extract the blood clot and restore blood flow in the brain. The Device's small size and extreme flexibility enable easy access and fast extraction of any clot, regardless of the clot's size or consistency. The trial will be the basis for submission of a CE Mark approval in order to market the device in CE countries. The company is in the process of adding more clinical centers, to be included in the trial, including Barcelona, Spain and Israel.